A ALIMENTARY TRACT AND METABOLISM
|
|
B BLOOD AND BLOOD FORMING ORGANS
|
|
C CARDIOVASCULAR SYSTEM
|
|
D DERMATOLOGICALS
|
|
G GENITO URINARY SYSTEM AND SEX HORMONES
|
|
H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
|
|
J ANTIINFECTIVES FOR SYSTEMIC USE
|
|
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
|
L01 ANTINEOPLASTIC AGENTS
|
L02 ENDOCRINE THERAPY
|
L03 IMMUNOSTIMULANTS
|
L04 IMMUNOSUPPRESSANTS
|
L04A IMMUNOSUPPRESSANTS
|
L04AA Selective immunosuppressants
|
L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors [DG:DG01936]
|
L04AC Interleukin inhibitors [DG:DG02019]
|
L04AD Calcineurin inhibitors [DG:DG03129]
|
L04AE Sphingosine-1-phosphate (S1P) receptor modulators
|
L04AF Janus-associated kinase (JAK) inhibitors
|
L04AF01 Tofacitinib [DG:DG00742]
|
D09970 Tofacitinib (USAN)
D09783 Tofacitinib citrate (JAN/USAN) <JP/US>
|
L04AF02 Baricitinib
|
L04AF03 Upadacitinib [DG:DG02829]
|
L04AF04 Filgotinib [DG:DG01991]
|
L04AF05 Itacitinib [DG:DG02833]
|
L04AF06 Peficitinib [DG:DG01853]
|
L04AF07 Deucravacitinib
|
L04AF08 Ritlecitinib
|
L04AG Monoclonal antibodies
|
L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors
|
L04AJ Complement inhibitors
|
L04AK Dihydroorotate dehydrogenase (DHODH) inhibitors
|
L04AX Other immunosuppressants
|
|
M MUSCULO-SKELETAL SYSTEM
|
|
N NERVOUS SYSTEM
|
|
P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
|
|
R RESPIRATORY SYSTEM
|
|
S SENSORY ORGANS
|
|
V VARIOUS
|